Follow The Filings

PFE Pfizer

Health Care, filed as PFIZER INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 4 managers in 2026 Q2, sold by 4

  • 3 Owners
  • #64
  • Max 3.3%
  • Master 0.02%
  • $28M
  • 3 add

In 2026 Q3 Torray Investment Partners, Kentucky Trust, and Murphy Pohlad added to Pfizer.

Who owns this now

Largest portfolio weights among holders, up to 3.3% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Add 3.3%
  2. Kentucky Trust Co. Add 0.95%
  3. Murphy Pohlad Add 0.54%

Who owns PFE

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 3.3%, was 2.8% Add +0.6% 864,169 $25M History
Kentucky Trust Co., Kentucky Trust 0.95%, was 0.76% Add +1.5% 66,381 $1.9M History
Murphy Pohlad, Murphy Pohlad Asset Management 0.54%, was 0.44% Add +3.2% 54,032 $1.5M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PFE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PFE insider trades
  • $3M bought by 3 insiders
  • $135K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Albert Bourla CEO
    Buy
    $1M 38,000 shares at $26.34 +9.7% to stake
    Traded Aug 12 Filed Aug 12
    ↗
  2. Jennifer B. Damico SVP & Controller
    Sale
    $83K 3,278 shares at $25.40 10% of stake
    Traded Aug 5 Filed Aug 6
    ↗
  3. Ronald E Blaylock Director
    Buy
    $999K 39,231 shares at $25.46 +142% to stake
    Traded Aug 5 Filed Aug 5
    ↗
  4. Mortimer J Buckley Director
    Buy
    $960K 37,632 shares at $25.52 New stake
    Traded Aug 5 Filed Aug 5
    ↗
  5. Jennifer B. Damico SVP & Controller
    Sale
    $51K 2,000 shares at $25.70 6% of stake
    Traded Jun 9 Filed Jun 10
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 share withholding for taxes.

Congress

25 members of Congress traded PFE in the last three years: 16 buys and 35 sales. 28 members listed it in 2025 annual reports.

All Congress trades
  1. Carol D. Miller R-WV-1Spouse Sell $15K–$50K Mar 10, 2025 filed Aug 13
  2. Michael A. Rulli R-OH-6 Sell $1K–$15K Nov 26, 2024 filed Aug 7
  3. Alan Armstrong R-OK Sell $50K–$100K Mar 24 filed Jul 21
  4. Tommy Tuberville R-ALJoint Sell $15K–$50K Jun 8 filed Jul 16
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Mar 13 filed Apr 7
  6. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Feb 10 filed Mar 9

SEC filings

Recent issuer filings from EDGAR, 9 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 7.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $50.91B — —
Gross profit * $25.96B — —
Gross margin * 51.0% — —
Net income $2.12B $8.03B $7.77B
Net margin * 4.2% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $43.33B $50.36B $42.9B
Total non-current assets * $183.17B $163.04B $165.26B
Total assets $226.5B $213.4B $208.16B
Total current liabilities $47.79B $43B $36.98B
Total non-current liabilities * $89.42B $81.9B $84.4B
Total equity $89.01B $88.2B $86.48B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $8.7B $12.74B $11.7B
Cash from investing -$32.28B $2.65B -$1.35B
Cash from financing $26.07B -$17.14B -$10.3B
Net change in cash $2.45B -$1.81B $0.091B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.